Health ❯ Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Obesity Treatment

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Phase 3 trials are set to begin this quarter following 48-week topline data showing large placebo-adjusted weight loss.

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials